SOLICITATION NOTICE
A -- Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
- Notice Date
- 10/27/2025 2:47:25 PM
- Notice Type
- Solicitation
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H) Washington DC 20005 USA
- ZIP Code
- 20005
- Solicitation Number
- ARPA-H-SOL-25-122
- Response Due
- 12/19/2025 8:59:00 PM
- Archive Date
- 01/03/2026
- Point of Contact
- THRIVE PROGRAM
- E-Mail Address
-
THRIVE@arpa-h.gov
(THRIVE@arpa-h.gov)
- Small Business Set-Aside
- NONE No Set aside used
- Description
- Amendment 3: Team Organization and Capabilities Section The purpose of this amendment is to clarify that the following information, requested in the Teaming Organization and Capabilities section of the Solution Summary, may be included in the Table for Key Personnel: Provide the name, position, and institution of each key team member and describe in 1-2 sentences the skills and experience they bring to the team. If included in the Table for Key Personnel, this information will not count towards the (3) page Solution Summary page limit, however, the Table for Key Personnel must still not exceed (1) page in length. In addition, the Q&A deadline is extended to October 30, 2025 at 11:59PM ET. ---------------------------------------------------------------------------------------------------------------- Amendment 2: Changes to the ISO The purpose of this amendment is to amend the THRIVE ISO. An updated version of the ISO and an updated version of the ISO with tracked changes are included as attachments. Changes to the ISO include: Cost share is now strongly encouraged instead of mandatory. Multi-party teaming arrangements are no longer required. ARPA-H's involvement with regulatory facilitation has been clarified. Please review the amended ISO for all changes. ---------------------------------------------------------------------------------------------------------------- Amendment 1: Added the Frequently Asked Questions (FAQ) to the list of attachments. ---------------------------------------------------------------------------------------------------------------- The Advanced Research Projects Agency for Health (ARPA-H) Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) program envisions a future where patients can opt for one-time therapeutic interventions designed to slow, reverse, or cure disease, harnessing revolutionary technologies and a rapidly evolving understanding of the genetic underpinnings of the biological processes that lead to disease. Interested parties are invited to review the attached THRIVE Innovative Solutions Opening (ISO) ARPA-H -SOL-25-122. For detailed information regarding Proposers' Day review Special Notice (SN) ARPA-H-SN-25-131. Solution summaries are due October 31, 2025, 11:59 PM ET. For more information about THRIVE, please visit:https://arpa-h.gov/explore-funding/programs/thrive
- Web Link
-
SAM.gov Permalink
(https://sam.gov/workspace/contract/opp/3524c5d34a78455da2ff3c7e1d05a21c/view)
- Place of Performance
- Address: Washington, DC 20005, USA
- Zip Code: 20005
- Country: USA
- Zip Code: 20005
- Record
- SN07628342-F 20251029/251027230033 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |